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Abstract
Background: The crude rate of early-onset Group B streptococcus disease (EOGBS) in Israel has been consistently
under 0.5 for 1000 live births for the past 8 years. The Israeli Ministry of Health has adapted the risk factor based
approach for preventing EOGBS and universal bacteriological screening for GBS is not recommended. In spite of
this policy, there are indications that many pregnant women in Israel undergo bacteriological screening for GBS.
The objective of this study is to assess the rate and characteristics of pregnant women who undergo screening for
group B streptococcus (GBS) colonization in Israel.
Methods: Survey of expectant mothers who came to give birth in 29 delivery rooms throughout Israel during the
month of July 2012 regarding GBS screening practice and demographics.
Results: A total of 2968 pregnant women participated in the assessment. Among them, 935 women (31.5 %) had
been tested for GBS colonization. About 90 % of those women had no risk factors, only 542 women (60 %) underwent
testing during the recommended gestational timing (35–37 weeks) and 23 % of the tested women reported being
GBS carriers.
GBS screening as part of the routine pregnancy follow- up was associated with: residence district, intermediate or high
socioeconomic rank, being a member of certain health maintenance organization and being Jewish.
Characteristics found to be significantly associated with being a GBS carrier were: low socioeconomic rank, and having
a risk factor for GBS infection.
Conclusions: A substantial number of pregnant women in Israel undergo screening for GBS colonization despite the
national policy against universal screening. While GBS colonization was more prevalent in women of lower
socioeconomic status, screening is done more often in those of higher socioeconomic status, suggesting
unnecessary monetary expenses.
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Background
Group B Streptococcus (GBS) is a leading cause of life-
threatening infection in newborns causing sepsis, pneu-
monia and meningitis [1]. Early onset GBS (EOGBS)
occurs within the first week of life (0–6 days) [2]. Intra-
partum antibiotic prophylaxis (IAP) has been proven to
lower the incidence of EOGBS [2, 3]. Screening for
women requiring IAP has been done using one of two
approaches: culture-based universal screening which
should be done between weeks 35 and 37 of pregnancy
and risk-based approach in which women receive IAP
based on the presence of risk factors [1, 4]. Universal
Screening policy is practiced in the United States and
Canada [1–3, 5] and it is also recommended with
some modifications in many European countries and
in Japan [6], (http://www.groupbstrepinternational.org/
what-is-group-b-strep/early-onset-gbs-disease/), [2]. A risk-
based approach is recommended in Denmark, Israel, the
Netherlands, New Zealand and the United Kingdom [1, 2].
Prior to the introduction of preventive measures, the inci-
dence of EOGBS ranged between 0.5 to more than 4 per
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1000 live births, and the rates varied substantially among
various geographical regions [2].
Israel has adopted the risk-based approach in which
pregnant women are not routinely screened for GBS car-
riage [7], but rather receive IAP if they have at least one
of the following risk factors: labor before week 37, pro-
longed (above 18 h) rupture of membranes, fever above
38 °C during labor, a previous infant with GBS disease,
and GBS bacteriuria at any stage of pregnancy.
Israel has been monitoring this policy since 2006
through active yearly national surveillance of all newborns
with EOGBS. The crude multi-year incidence from 2010
to 2014 was 0.26 per 1000 live births. Among infants
whose mothers had risk factors, the incidence was 0.50
per 1000 live births, while the multi-year incidence among
infants whose mothers had no risk factors was 0.20 per
1000 live births [8].
Although there is no universal screening in Israel,
many women are tested for GBS carriage during preg-
nancy (personal communication). As a result, the Israeli
Society of Obstetrics and Gynecology position is that
IAP should be administered both to women who have at
least one risk factor and to women who have been tested
for GBS carriage close to labor and found to be colo-
nized [9].
The objectives of our study were to assess the rate of
women who undergo the testing for GBS carriage in
Israel, their demographic characteristics and the reasons
for performing the test.
Methods
Study subjects
Pregnant women who came to give birth in delivery
rooms throughout Israel from July 1, 2012 to July 31, 2012
were included in the survey. Women whose referral to the
delivery room did not result in labor and non-residents
were excluded from the study.
Survey
The survey was administered during weekday morning
shifts throughout the month of July 2012 (a total of
23 days) in 29 delivery rooms (out of total 30) through-
out Israel. A nurse (or any other previously appointed
personnel member) filled out a short questionnaire for
each woman who came to give birth. The questionnaire
included information on last menstrual date, whether a
GBS testing was done, the timing of the test, the result
of the test, and the reason for performing it. Demo-
graphic information included woman’s age, country of
origin, Health Ministry residence district, population
group, and health insurance membership. In cases where
the GBS test was positive, women were asked to show
documentation of the result.
Determination of socioeconomic status
Socioeconomic status was based on women’s place of
residence, using the Israel Central Bureau of Statistics
(CBS) definition [10]. The CBS ranks each municipality
into 1 of 10 socioeconomic clusters, 1 being the lowest
and 10 being the highest. Each woman was assigned one
of 3 socioeconomic ranks based on the socioeconomic
cluster of her place of residence: low (for clusters 1–3),
intermediate (clusters 4–6), and high (clusters 7–10).
Statistical analysis
Comparison of continuous variables was performed using
the Students’ T-test (assuming normal distribution), and
comparison of categorical variables was done using the
Chi square test. Multivariate analysis was performed using
logistic regression analysis. A p value <0.05 was consid-
ered statistically significant. The statistical analysis was
carried out using the SAS software (version 9.1.3).
Ethical consideration
Performance of the survey was approved by the legal
Council of the Israel Ministry of Health, in accordance
with the public health act enacted in Israel. Under this
act the Israel Ministry of Health can perform surveil-
lance and monitoring of the performance of health pol-
icies and directives. As such it does not require any
special consent beyond the expectant mother general
agreement to receive accepted appropriate labor and de-
livery room treatment.
Results
Rate of GBS testing
A total of 3015 pregnant women came to give birth in
29 hospitals throughout Israel, during the time of the
survey. Of those, 47 were excluded as they were not Is-
raeli residents. Of the 2968 women who participated in
the survey, 2945 (99.2 %) responded to the question on
GBS testing. Of those, 935 (31.7 %) reported having
undergone the test, 1890 (64.3 %) did not and 120 (4 %)
could not recall if they had undergone GBS testing. Fig. 1
presents a flow chart that outlines the distribution of
study participants.
Timing of GBS testing
Of the 935 women who reported undergoing GBS test-
ing, 930 (99.5 %) were able to recall the timing of the
test (Fig. 1). Of those, 542 (58.2 %) underwent the test
between 35 and 37 weeks, 141 (15.2 %) had it before
week 35, and 247 (26.5 %) after week 37.
Reasons for GBS testing
Of the 935 women who reported having undergone the
GBS screening, 867 (92.7 %) responded to the question
regarding the reasons for being tested. A total of 628
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women (72.4 %) underwent the test as a part of the
routine pre-natal care and additional 54 women (6 %)
as a result of their request (Fig. 1, Table 1). Only 120
women (14 %) reported undergoing GBS testing due to
a medical reason: previous GBS infection in a newborn
infant, Rupture of membranes before week 37, Contrac-
tions with marked cervix changes before week 37, GBS
bacteriuria in the current pregnancy or GBS carrier in
previous pregnancy. Other medical reasons given for
undergoing GBS testing were: urinary tract infection
(UTI), recurrent UTI, UTI symptoms, vaginal discharge/
odor/infection, intrauterine growth retardation (IUGR)
and hospitalization during pregnancy (unspecified reason)
(Fig. 1). Table 1 presents the specific reasons reported for
undergoing GBS testing. 77.2 % of women who underwent
GBS testing between 35 and 37 weeks reported that the
main reason for undergoing GBS testing was as part of
the routine pre-natal care.
Women who underwent GBS testing before week 35
or after week 37 (Table 1) also reported that the main
reason for undergoing the test was as part of the routine
pre-natal care. This reason was reported by 48.5 % of
the women who underwent the test prior to week 35,
and 75.7 % of women who underwent the test after week
37 (Table 1).
We compared women who underwent GBS testing as
part of routine prenatal care to women who underwent
the test for other reasons with respect to the various
gestational week category (<35, 35–37 and >37) in which
the test was performed. Women who underwent GBS
testing between 35 and 37 weeks of gestation and after
week 37 reported that routine pre-natal care was the
main reason for undergoing the test significantly more
often than women who underwent GBS testing before
week 35 (p < 0.0001). No statistically significant differ-
ences were observed when comparing women who
Fig. 1 Flow chart of parturient women participating in the survey
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underwent the test during weeks 35 to 37 with women
who underwent the test later than week 37 of pregnancy.
Similar results were obtained for the comparison be-
tween women who underwent GBS testing as part of
routine prenatal care to those who underwent the test
for medical reasons.
GBS test results
GBS screening test results were reported by 901 women
(96.3 %). A total of 209 (23.2 %) of the women reported
a positive culture for GBS, 595 (66.0 %) were negative
and 97 (10.8 %) could not recall the results (Fig. 1).
A total of 804 women provided a response both re-
garding the reason for having had the test and its result.
For 131 women, information on the reason for GBS
screening and/or its results was not available. Of the 935
women who reported undergoing the GBS test, 473
(50.6 %) presented a documented result of the test. A
total of 138 (66 %) of the 209 GBS carriers presented a
documentation of a positive test and 318 (53.4 %) of the
595 non-GBS carriers presented a documentation of a
negative test. For 17 women who reported undergoing
the GBS test and presented a documented result, the re-
sult was not recorded.
Women who were GBS-tested for medical reasons were
significantly more often positive for GBS compared with
those who had it as part of the routine prenatal care
(43.2 % vs 21.9 %, p < 0.0001, odds ratio 2.71) (Table 2).
Demographic characteristics
The characteristics of the women who performed the
test were compared with those who did not. The univar-
iate analysis showed statistically significant differences in
Health Ministry residence district, country of origin, so-
cioeconomic rank, HMO membership and population
group between women who underwent GBS testing and
those who did not. No difference was found in the mean
age of the women who took the test and those who did
not. In the multivariate analysis (Table 3), statistically
significant differences were found for all variables, ex-
cept and country of origin (Table 3). Specifically, charac-
teristics that were significantly associated with GBS
testing were: belonging to the Jerusalem district, belong-
ing to intermediate and high socioeconomic rank, being
a member of certain HMOs and being Jewish (Table 3).
When the analysis was restricted to those women who
had documentation of their GBS testing, belonging to
the Jerusalem district, belonging to intermediate and
high socioeconomic rank, being a member of certain
HMOs and being Jewish were associated with women
who underwent GBS testing in a multivariate analysis.
Additionally, when the analysis was restricted to those
women who performed the test because of routine pre-
natal care, differences in Health Ministry residence dis-
trict were associated with women who underwent GBS
testing because of routine pre-natal care, in a multivari-
ate analysis.
We also evaluated the differences in demographic
characteristics between women who reported being GBS
carriers and those who reported being a non-carriers
(Table 4). Slightly younger age (1.2 years difference in
mean age), low socioeconomic status, having a medical
reason for GBS testing and Arab population group, were
Table 2 Distribution of GBS screening results with respect to









Yes 38 (43.2) 43 (48.9) 7 (7.9) 88
No 157 (21.9) 494 (69.0) 65 (9.1) 716
Total 195 537 72 804
Table 1 Reasons reported for GBS testing during pregnancy
Timing Any <35 weeks 35–37 weeksa >37 weeks
Reason n (%) n (%) n (%) n (%)
Routine pre-natal care 628 72.4 65 48.5 396 77.2 165 75.7
Woman’s request 54 6.2 3 2.3 33 6.4 18 8.3
Previous GBS infection in a newborn infant 23 2.7 1 0.8 17 3.3 5 2.3
ROM before week 37 7 0.8 3 2.2 4 0.8 - -
Contractions with marked cervix changes before week 37 38 4.4 26 19.4 10 2.0 2 0.9
GBS bacteriuria in the current pregnancy 27 3.1 13 9.7 8 1.6 6 2.7
GBS carrier in previous pregnancy 27 3.1 3 2.2 16 3.1 8 3.7
Other 25 2.9 11 8.2 10 1.9 4 1.8
Reason unknown/not recalled 38 4.4 9 6.7 19 3.7 10 4.6
Total No. of women who responded to question 867 100 134 100 513 100 218 100
aFor two women the gestational age was known, however no reason was recorded on questionnaire. They were categorized as missing information and are not
included in the table
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significantly associated with GBS positivity in a univari-
ate analysis. In a multivariate analysis the characteristics
that were most significantly associated with a GBS car-
rier state were: low socioeconomic status and having a
medical reason for GBS testing (Table 4). Belonging to a
certain HMO was also associated with a GBS carrier
state. When the analysis was restricted to those women
who had documentation of their GBS status, low socio-
economic status and having a Medical reason for GBS
testing were associated with GBS carrier state in a multi-
variate analysis.
Discussion
The incidence of invasive EOGBS disease among new-
borns in Israel is low, and consists of a multiyear average
of 0.26 per 1000 live births (for the years 2014–2010).
The low rate directed the decision to adopt a risk-based
approach for the prevention of EOGBS.
Our survey demonstrated that despite the lack of univer-
sal GBS screening policy in Israel, about one third of the
women surveyed were tested for GBS carriage during
pregnancy. Most of these women had the test as part of
routine pre-natal care or as a result of their request, par-
ticularly, in those women who underwent the testing on
week 35 or later of preganacy. Furthermore, about 40 % of
the women were not tested during the recommended time
for screening, but rather before week 35 or after week 37
of pregnancy. The relatively high rate of GBS testing re-
ported by women with no known risk factors for GBS car-
riage, suggests that the test is performed in Israel in a
substantial number of cases despite the lack of recommen-
dation for a universal GBS screening. This may be due to
familiarity of physicians with the universal screening prac-
ticed in other countries, and concern of law suits. Our
findings that GBS testing was more frequent in women be-
longing to the Jerusalem district and among members of
certain HMOs, suggest that GBS testing practices may
vary due to differences in the practices of physicians work-
ing for a specific HMO and in specific locations. Variability
could also exist in the practice of different doctors belong-
ing to the same HMO and district; however, additional re-
search is required to address this issue.
The finding that women who underwent GBS testing
were more likely to be of a higher socioeconomic status
may reflect their awareness of universal screening per-
formed elsewhere in the world. Differences in know-
ledge about the GBS colonization status by women
giving birth, was previously described. A retrospective
study from California, USA, demonstrated that prior to
the implementation of universal GBS screening, black
women had a lower probability of having GBS carriage
information available at time of delivery [11].







Univariate Analysis Multivariate Analysis
Odds Ratio 95 % CI p value Odds Ratio 95 % CI p value
Average age (years) 29.5 29.3 - 0.61
Residency district n (%) Jerusalem 219 (23.4) 282 (14.9) 1 Ref 1 Ref
North 76 (8.1) 398 (21.1) 0.2 0.2–0.3 <0.0001 0.3 0.2–0.4 <0.001
Haifa 60 (6.4) 183 (9.7) 0.4 0.3–0.6 <0.0001 0.2 0.1–0.4 <0.001
Center 169 (18.1) 455 (24.1) 0.5 0.4–0.6 <0.0001 0.2 0.2–0.4 <0.001
Tel Aviv 125 (13.4) 254 (13.4) 0.6 0.5–0.8 <0.01 0.3 0.2–0.4 <0.001
South 187 (20.0) 239 (12.6) 1.0 0.8–1.3 0.9 0.9 0.7–1.2 0.5
Judea & Samaria 99 (10.6) 79 (4.2) 1.6 1.1–2.3 <0.01 0.9 0.7–1.4 0.8
Country of origin n (%) Israel 754 (81.6) 1511 (84.0) 1 Ref 1 Ref
Asia-Africa 19 (2.1) 56 (3.1) 0.7 0.4–1.2 0.2 0.7 0.4–1.2 0.2
America-Europe 151 (16.3) 232 (12.9) 1.3 1.1–1.7 <0.01 0.9 0.7 0.5
Socioeconomic rank n (%) Low 63 (7.0) 288 (16.7) 1 Ref 1 Ref
Intermediate 620 (69.0) 1073 (62.2) 2.6 2.1–3.3 <0.0001 1.9 1.4–2.6 <0.001
High 216 (24.0) 365 (21.1) 2.7 2.0–3.5 <0.0001 3.2 2.1–4.7 <0.001
Health Maintenance
Organization n (%)
Clalit Health service 402 (43.6) 1089 (58.8) 1 Ref 1 Ref
Maccabi Healthcare services 229 (24.8) 361 (19.5) 1.7 1.4–2.1 <0.0001 1.5 1.2–1.8 <0.001
Le’umit 93 (10.1) 164 (8.8) 1.5 1.1–2.0 <0.01 1.1 0.8–1.5 0.3
Me’uhedet 198 (21.5) 238 (12.8) 2.2 1.8–2.8 <0.0001 1.6 1.2–2.0 <0.001
Religion n (%) Arab 89 (9.5) 570 (30.1) 1 <0.0001 1 <0.001
Jewish & others 846 (90.5) 1320 (69.8) 4.1 3.2–5.2 2.6 1.9–3.5
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Although age was found to be associated with under-
going GBS testing, the small age difference between
those women who underwent GBS testing and those
who did not, was minimal (Table 3).
Our study showed that lower socioeconomic status and
having a medical reason for GBS testing were associated
with GBS colonization. Lower socioeconomic status was
also associated with lower GBS testing rates among
women in our survey. Therefore, our study suggests that
women who are least likely to be colonized with GBS
undergo the test most frequently, a situation that may be
associated with unnecessary monetary expenses.
Our finding that GBS carriers were more likely to belong
to a low socioeconomic rank is interesting. Other reports
addressing the association between GBS colonization and
socioeconomic status showed mixed results. A study from
the USA showed lower rates of GBS carriage among more
educated women [12], and a study from Mexico demon-
strated higher rates of GBS colonization among women
residing in poor areas and of low socioeconomic status
[13]. On the other hand, in a study from Turkey, GBS car-
riage was found more frequently among women of middle
socioeconomic status [14]. Other studies did not find an
association between GBS colonization and socioeconomic
status [15, 16].
We found that when GBS testing was done, it was per-
formed according to the recommended timing (35 to
37 weeks) only in 58 % of cases. Although these recom-
mendation were made to capture most women prior to
delivery, performing the test prior to week 35 is the
most problematic. Although in our study, 22 % of the
women undergoing the test prior to week 35, reported a
valid reason for doing so (rupture of membranes or con-
tractions with marked cervical changes prior to week
37), the majority did not. A study by Yancey et al. dem-
onstrated that performing the test six weeks or more
prior to delivery, decreases significantly its sensitivity,
specificity, as well as positive and negative predictive
values [17]. In our study 15 % of women performing
GBS testing, underwent the test prior to week 35. In a
recent study from Tennessee, where universal GBS
screening is practiced, 26 % of pregnant women under-
went GBS testing prior to week 35 [18]. These findings
suggest that in a significant proportion of women
undergoing GBS testing, the test is performed too early,
regardless of the approach used for preventing EOGBS.








Univariate Analysis Multivariate Analysis
Odds Ratio 95 % CI p value Odds Ratio 95 % CI p value
Average age (years) 28.6 29.9 - 0.002
Residency district n (%) Jerusalem 53 (25.4) 132 (22.2) 1 Ref. 1
North 18 (8.6) 40 (6.7) 1.1 0.6–2.1 0.7 0.7 0.3–1.6 0.4
Haifa 13 (6.2) 43 (7.2) 0.7 0.3–1.5 0.4 0.9 0.4–2.1 0.9
Center 27 (12.9) 121 (20.3) 0.5 0.3–0.9 0.0 0.7 0.3–1.2 0.2
Tel Aviv 30 (14.3) 86 (14.4) 0.9 0.5–1.4 0.6 1.2 0.6–2.4 0.6
South 44 (21.0) 108 (18.1) 1.0 0.6–1.6 0.9 0.9 0.5–1.6 0.8
Judea & Samaria 24 (11.5) 65 (10.9) 0.9 0.5–1.6 0.7 0.9 0.5–1.8 0.9
Country of origin n (%) Israel 162 (80.6) 485 (81.6) 1 Ref. 1
Asia-Africa 5 (2.5) 11 (1.85) 1.3 0.4–3.8 0.6 1.9 0.6–6.2 0.2
America-Europe 34 (16.9) 98 (16.5) 0.9 0.6–1.5 0.9 1 0.6–1.6 0.9
Socioeconomic rank n (%) Low 25 (12.6) 25 (4.3) 1 Ref. 1
Intermediate 136 (68.3) 393 (68) 0.4 0.2–0.7 0.0 0.3 0.2–0.6 0.0
High 38 (19.1) 160 (27.7) 0.3 0.1–0.5 <0.001 0.2 0.1–0.6 0.0
Health Maintenance
Organization n (%)
Clalit Health services 80 (38.8) 253 (43.0) 1 Ref. 1
Maccabi Healthcare services 55 (26.7) 151 (25.7) 1.1 0.7–1.7 0.5 1.4 0.8–2.2 0.2
Le’umit 26 (12.6) 52 (8.8) 1.6 0.9–2.7 0.1 1.8 0.9–3.2 0.0
Me’uhedet 45 (21.8) 132 (22.4) 1.1 0.7–1.6 0.7 1.1 0.7–1.9 0.6
Reason to screening n (%) Routine F/U 155 (79.5) 494 (92.0) 1 <0.0001 1
Risk factor 40 (20.5) 43 (8.0) 2.9 1.8–4.7 3.0 1.8–4.9 <0.001
Religion n (%) Arab 27 (12.9) 38 (6.4) 1 0.0 1
Jewish & others 182 (87.1) 557 (93.6) 0.4 0.3–0.8 1.3 0.6–2.8 0.5
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Thus, their results may be irrelevant for decision-
making during labor.
The major strength of our study was its nationwide
scope, making it representative of the national situation.
It was carried out in 29 hospitals out of the existing 30
general hospitals in Israel. Only one small peripheral
hospital was excluded from the survey. However, due to
the low number of births in this hospital (2 per day on
average), it is anticipated that its inclusion in our study
would have added approximately 46 subjects, which
would have constituted only 1.5 % of the study popula-
tion, and thus would not have had a significant impact
on our results.
This assessment was done only during one month of
the year. Though no seasonality is known for GBS, gath-
ering data during a longer period may have altered some
of the results. In addition, only 50 % of the women who
underwent the test had documentation at the time of de-
livery. Another limitation of this study is self-report by
women as to whether they were screened and what their
result was.
Currently, it is unknown how many women undergo
GBS screening during pregnancy in other countries that
use risk-based approach. Based on our results, we be-
lieve that it is important to conduct similar studies in
those countries, in order to assess, on one hand, compli-
ance with health policies, and on the other hand, wea-
ther the existing health policies require adjustments.
The continually low rates of morbidity due to GBS in
Israel during years 2006–2014 [8], and the fact that most
women who were tested for GBS carriage did not have
medical reasons warranting testing, suggest that the
current policy of giving intrapartum antibiotic prophy-
laxis (ISAP) during labor and delivery based on the pres-
ence of risk factors, rather than based on the results of
GBS testing at weeks 35–37, is appropriate for Israel.
The current practice of performing GBS screening dur-
ing pregnancy, especially not during the recommended
time-frame and in the absence of medical reasons, sug-
gests an unnecessary utilization of resources. Although
testing for GBS colonization is best performed during
weeks 35 to 37 weeks of pregnancy, the presence or ab-
sence of GBS during that time-period does not always
reflect colonization during labor and delivery [17]. Thus, it
is important to maintain the risk factor-based approach for
preventing Early-Onset GBS disease in newborns.
Conclusions
Our research proved that approximately a third of the
expectant mothers in our survey have undergone GBS
testing during pregnancy, and that the test was per-
formed in those populations least at risk for GBS car-
riage. Furthermore, in over 40 % of the cases the test
was not done at the recommended timing. Based on
these findings, it appears that most GBS carriers are
not detected. Thus, the performance of GBS testing
during pregnancy cannot explain the low rate of
EOGBS in Israel.
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